Explore our strategy and projects
to learn about the future of our company
Results FY 2024 (€/MLN)
1,185
Revenues
394
Adjusted EBITDA
236
Adjusted net profit
241
Free cash flow
Stock price
Discover morePress releases
18/03/25 - 11:54
Diasorin launches the Simplexa™ C. auris direct assay on the LIAISON® MDX instrument in all countries accepting the CE Mark
14/03/25 - 16:29
Price sensitiveThe Board of Directors of Diasorin SpA approves FY2024 Results with revenues and net profit in expansion compared to Previous Year; Proposed Ordinary Dividend of € 1.20 per share
LIAISON PLEX® System: the new multiplexing platform of the Group
Diasorin's LIAISON PLEX® System and Respiratory Flex Assay Revolutionize Diagnostics with Flexibility and have Earned FDA Clearance.
Keep
in touch
Sign up for our investor alerts
and stay informed
on the latest developments